Chronic Kidney Disease
Conditions
Keywords
hyperparathyroidism, calcifediol
Brief summary
The overall study objective is to collect real-world data on the safety and effectiveness of ERC to gradually increase 25D to the level required by Stage 3 and 4 CKD patients. ERC (Rayaldee), a prolonged-release calcifediol (PRC) formulation, is an orally administered prohormone of active Vitamin D (1,25-dihydroxyvitamin D (1,25D)) designed to increase serum total 25D safely and to a high enough magnitude to reliably reduce elevated PTH in patients with non-dialysis chronic kidney disease (ND-CKD). Clinical studies show that ERC is an effective, well tolerated treatment for secondary hyperparathyroidism (SHPT) in ND-CKD patients with Vitamin D insufficiency or deficiency. ERC gradually raises serum 25D levels, resulting in physiologically regulated increases in serum 1,25D and sustained and progressive reductions in PTH levels, while avoiding clinically meaningful increases in serum phosphate and calcium. To date, experience with the use of ERC results exclusively from patients from the US and mainly from patients who have participated in clinical trials. It is therefore of major interest to observe the value of ERC in daily use outside of the controlled trial settings in the US as well as in Europe. (Protocol v.2.0,06Dec2023).
Detailed description
Non-interventional, prospective, multicentre, cohort study. Approximately 100 patients diagnosed with ND-CKD with SHPT being treated with ERC according to the SmPC will be included. The scheduled total study duration is 2.5 years, with a recruitment phase of approximately 1.5 years. The individual prospective observational period per patient is scheduled to last up to 12 months, or up to 18 months for pre-treated patients. The number of observational time points for an individual patient will be dependent on the individual observational period and is assumed to be approximately every 3 months. A patient is eligible if ERC treatment initiation can coincide with the date of patient inclusion in the study or can happen up to 6 months before patient inclusion in the study. The observational period of ERC treatment will be retrospective if it occurs before study inclusion and prospective for the period after study inclusion. The decision to initiate treatment remains with the treating physician, in line with their normal standard of care, in accordance with the SMPC.
Interventions
None listed
Sponsors
Vifor (International) Inc.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent * Age ≥18 years * Indication for ERC treatment in accordance with the currently approved SmPC. * Starting ERC treatment or being on ERC treatment for a maximum of 6 months before inclusion in the study. * Stable kidney function in the medical judgment of the investigator
Exclusion criteria
Parallel participation in an interventional study • Enrolment in a prior clinical trial with ERC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in 25-hydroxyvitamin D (25D) and iPTH levels | From up to 6 months prior of ERC treatment start to up to 18 months after treatment | ng/mL or nmol/L, pg/mL or pmol/L |
| Change in serum calcium level | From up to 6 months prior of ERC treatment start to up to 18 months after treatment | mg/mL or nmol/L |
| Change in serum phosphate level | From up to 6 months prior of ERC treatment start to up to 18 months after treatment | mg/mL or nmol/L |
Countries
Germany
Outcome results
None listed